miR-203 inhibits cell proliferation and ERK pathway in prostate cancer by targeting IRS-1.
Level 5 - mechanism / opinion, no new human data
In vitro bench research evaluating molecular pathways in cell lines without human subjects.
PubMed 33109107 · doi:10.1186/s12885-020-07472-2
What was done
Researchers investigated the molecular mechanisms of miR-203 in prostate cancer cell models. Dual-luciferase reporter gene assays were performed to test whether miR-203 binds to the 3' untranslated region (3'UTR) of insulin receptor substrate 1 (IRS-1). Cell proliferation was measured via MTT assays in prostate cancer cells with either IRS-1 knockdown or miR-203 overexpression, and protein expression was evaluated by Western blot.
What was found
The abstract reports no numerical values. Qualitatively, miR-203 directly bound to the 3'UTR of IRS-1 and suppressed IRS-1 protein expression. Overexpression of miR-203 or knockdown of IRS-1 inhibited cell proliferation and cell migration, induced cell cycle arrest, and blocked downstream ERK signaling pathway activation.
Why it matters
The study identifies IRS-1 as a direct target of miR-203, providing a mechanistic link between microRNA dysregulation, IRS-1 expression, and ERK pathway activation in prostate cancer progression.
Limits
The study is entirely preclinical and in vitro. The abstract does not specify the prostate cancer cell lines used, lacks sample sizes or quantitative statistical estimates (such as effect sizes or confidence intervals), and provides no in vivo animal or clinical patient validation.
Cited by
- supports The insulin receptor is coupled to the mitogen-activated protein kinase (MAP kinase) pathway, which stimulates cell growth and division.